CDK7 and neuroblastoma: This novel treatment strategy has the potential to benefit not only breast cancer patients who do not respond to current treatments, but can also be examined as a novel strategy in other cancer subtypes which has previously exhibited sensitivity to CDK7 inhibition including lung cancer, ovarian cancer, neuroblastoma, glioma, and leukemia.